Tamanho Do Mercado E Pesquisa Da Indústria De Diagnóstico De Leucemia Mieloide Aguda Até 2031

Global Acute Myeloid Leukemia Diagnostics Market

Tamanho do mercado em biliões de dólares

CAGR : 11.30 %

Período de previsão	2024 –2031
Tamanho do mercado (ano base )	USD 2,777.16 Million
Tamanho do mercado ( Ano de previsão)	USD 6,538.78 Million
CAGR	11.30 %
Principais participantes do mercado	Manequim1 Manequim2 Manequim3 Manequim4 Manequim5 Pedido de desbloqueio

>Mercado global de diagnóstico de leucemia mieloide aguda, por tipo de produto (instrumentos e consumíveis e acessórios), tipo de teste (teste de imagem, exame de sangue, teste de medula óssea, teste de biomarcadores, imunofenotipagem, testes genéticos e outros), tipo de cancro (mieloblástico (M0) , Mieloblástico (M1), Mieloblástico (M2), Promielocítico (M3), Mielomonocítico (M4), Monocítico (M5), Eritroleucemia (M6) e Megacariocítico (M7)), Faixa etária (65 e acima, abaixo de 21, 21- 29 e 30-65), Género (Masculino e Feminino), Utilizador Final (Hospital, Laboratórios Associados, Laboratórios de Diagnóstico Independentes, Centros de Diagnóstico por Imagem, Institutos de Investigação do Cancro e Outros), Canal de Distribuição (Concurso Directo e Vendas a Retalho) - Indústria Tendências e previsões para 2031.

Análise e insights de mercado de diagnóstico de leucemia mieloide aguda

A crescente prevalência do cancro da leucemia em todo o mundo aumentou a procura de crescimento do mercado. O aumento dos gastos em saúde para melhores serviços de saúde também contribui para o crescimento do mercado. Os principais players do mercado concentram-se em diversos lançamentos e aprovações de serviços durante este período crucial. Além disso, o aumento da melhoria dos processos e técnicas de diagnóstico também contribui para a crescente procura de testes de diagnóstico do cancro no sangue. No entanto, espera-se que o diagnóstico tardio e o mau prognóstico da leucemia dificultem o crescimento do mercado no período de previsão. Espera-se que o aumento dos gastos com a saúde no diagnóstico e tratamento do cancro dê oportunidades ao mercado para melhorar o tratamento.

Espera-se que o mercado global de diagnóstico de leucemia mieloide aguda cresça no período de previsão de 2024 a 2031. A pesquisa de mercado da ponte de dados analisa que o mercado está a crescer com um CAGR de 11,3% no período de previsão de 2024 a 2031 e deverá atingir os 6.538,78 milhões de USD até 2031, contra 2.777,16 milhões de dólares em 2023.

Métrica de reporte	Detalhes
Período de previsão	2024 a 2031
Ano base	2023
Ano histórico	2022 (personalizável para 2016-2021)
Unidades Quantitativas	Receita em milhões de dólares
Segmentos cobertos	Tipo de produto (instrumentos e consumíveis e acessórios), tipo de teste (teste de imagem, exame de sangue, teste de medula óssea, teste de biomarcador, imunofenotipagem, teste genético e outros), tipo de cancro (mieloblástico (M0), mieloblástico (M1), mieloblástico ( M2), promielocítico (M3), mielomonocítico (M4), monocítico (M5), eritroleucemia (M6) e megacariocítico (M7)), faixa etária (65 e acima, abaixo dos 21, 21-29 e 30-65), Género (masculino e feminino), utilizador final (hospital, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro e outros), canal de distribuição (concurso direto e vendas a retalho )
Países abrangidos	EUA, Canadá, México, Alemanha, Reino Unido, França, Itália, Espanha, Rússia, Holanda, Suíça, Bélgica, Turquia, Resto da Europa, China, Japão, Índia, Austrália, Coreia do Sul, Indonésia, Filipinas, Tailândia, Malásia , Vietname, Singapura, Resto da Ásia-Pacífico, Brasil, Argentina, Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel e Resto do Médio Oriente e África
Participantes do mercado abrangidos	CANON MEDICAL SYSTEMS CORPORATION, Sysmex Corporation, Epigenomics AG, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Agilent Technologies, Inc., Siemens Healthcare GmbH, BIOMERIEUX, Exact Sciences Corporation, Merck KGaA, Hologic Inc . ., DiaSorin SpA, Illumina, Inc., Koninklijke Philips NV, BD, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., FONAR Corp., Time Medical Holding., Sonic Healthcare, PlexBio, MinFound Medical Systems Co., Ltd , Medonica Co. Ltd, Thermo Fisher Scientific Inc. e SternMed GmbH, entre outros

Definição de mercado

A Leucemia Mieloide Aguda (LMA) é um cancro do sangue e da medula óssea. É o tipo mais comum de leucemia aguda em adultos. Este tipo de cancro geralmente piora rapidamente se não for tratado. A LMA é também designada por leucemia mielóide aguda e leucemia não linfocítica aguda. A maioria dos subtipos de LMA baseia-se na maturidade (desenvolvida) das células cancerígenas no momento do diagnóstico e na diferença entre estas e as células normais.

A leucemia promielocítica aguda (LPA) é um subtipo de LMA. Esta leucemia ocorre quando os genes do cromossoma 15 trocam de lugar com alguns genes do cromossoma 17 e é produzido um gene anormal chamado PML-RARA. O gene PML-RARA envia uma mensagem que impede a maturação dos promielócitos (um tipo de glóbulos brancos). Podem ocorrer problemas com hemorragias graves e coágulos sanguíneos. Este é um problema de saúde grave que necessita de tratamento o mais rapidamente possível. A APL ocorre geralmente em adultos de meia-idade.

Dinâmica global do mercado de diagnóstico da leucemia mieloide aguda

Esta secção trata da compreensão dos impulsionadores, restrições, oportunidades e desafios do mercado. Tudo isto é discutido em detalhe abaixo:

Motoristas

Crescente prevalência de cancro de leucemia

Todas as idades podem ser afetadas pela leucemia. A leucemia pode ser difícil de diagnosticar porque, apesar da sua vasta gama de sinais e sintomas, é inespecífica e pode estar associada a outras condições médicas mais generalizadas. A LMA é um dos quatro tipos comuns de leucemia em adultos. Ocorre com menos frequência. É um pouco mais comum entre os homens do que entre as mulheres. No entanto, o risco médio ao longo da vida de contrair LMA em ambos os sexos é de cerca de ½ de 1%, em média.

A LMA é o segundo tipo mais comum de leucemia diagnosticada em adultos e crianças, mas a maioria dos casos ocorre em adultos. Embora possa ser diagnosticada em qualquer idade, é pouco frequente antes dos 45 anos. A idade média de diagnóstico é de 68 anos.

Devido a vários factores de risco, a incidência da LMA tem vindo a aumentar, tornando-se um problema socioeconómico significativo. Espera-se que isto atue como um motor para o crescimento do mercado.

Novos avanços tecnológicos no diagnóstico da leucemia

A forma mais comum de cancro do sangue, a LMA, é também uma das formas pouco frequentes de leucemia. Esta forma de cancro invade o sangue, que depois se espalha para os órgãos e sistemas corporais próximos. Os especialistas devem diagnosticar manualmente as células cancerígenas e não cancerígenas, examinando as imagens das células ao microscópio e fornecendo etiquetas através de anotação. No entanto, este exame microscópico da mão é demorado e pode fornecer um diagnóstico incorreto.

O risco de prescrição de medicamentos incorretos foi então reduzido com a utilização de software informatizado. A criação de um sistema de classificação automático e fiável tornou-se vital para travar os efeitos devastadores da doença leucémica. Múltiplas técnicas de segmentação constituíram a base dos algoritmos de classificação de leucemia existentes.

O desenvolvimento de vários novos métodos de diagnóstico aumentará o crescimento do mercado à medida que muitos produtos novos e avançados forem lançados. Assim, espera-se criar procura por produtos de diagnóstico de cancro leucémico agudo no mercado.

Aumento da consciencialização sobre o cancro de leucemia

A sensibilização para o cancro da leucemia aguda é uma oportunidade para aumentar o conhecimento sobre estas doenças e destacar a investigação sobre as suas causas, prevenção, diagnóstico, tratamento e sobrevivência. O objetivo é ajudar as pessoas afetadas pela leucemia e promover hábitos saudáveis.

Todos os anos, são planeadas várias campanhas de sensibilização para educar as pessoas sobre a leucemia. Várias organizações assumem a liderança nisso. Como resultado, espera-se que isto impulsione o crescimento do mercado.

Oportunidade

Aumento de produtos de diagnóstico para a leucemia

O aumento de produtos de diagnóstico concebidos especificamente para a leucemia apresenta uma oportunidade notável no sector da saúde. Esta expansão significa um foco crescente em soluções de diagnóstico personalizadas, oferecendo métodos mais precisos e abrangentes para identificar vários subtipos e estádios de leucemia. Estes avanços facilitam diagnósticos mais precoces e precisos, permitindo aos profissionais de saúde iniciar estratégias de tratamento imediatas e direcionadas. Além disso, o panorama em evolução dos produtos de diagnóstico cria oportunidades de inovação, promovendo o desenvolvimento de novas tecnologias e abordagens que podem melhorar ainda mais a gestão global e o prognóstico dos doentes com leucemia.

Restrições/Desafios

Regulamentação e normas rigorosas para aprovação e comercialização de produtos para diagnóstico de leucemia

As rigorosas regulamentações para a comercialização de qualquer produto no mercado estão a revelar-se um grande desafio para os fabricantes de produtos de diagnóstico de cancro que possuem regulamentos e um organismo diferenciado para os procedimentos regulamentares.

Os fabricantes devem primeiro verificar a aprovação da marca CE para a comercialização dos seus produtos no mercado. Espera-se que as rigorosas políticas regulamentares prejudiquem o crescimento e o desenvolvimento do mercado.

Diagnóstico tardio e mau prognóstico de leucemia

O cancro é a principal causa de morte na América do Norte. No entanto, se forem identificados precocemente e receberem os cuidados adequados, alguns tipos de cancro podem ser curados. O processo de diagnóstico pode sofrer atrasos no diagnóstico do cancro. Quando os doentes ignoram ou não respondem a possíveis sinais cancerígenos, o diagnóstico é adiado. A principal causa da apresentação tardia é a falta de conhecimento público dos sinais iniciais do cancro, especialmente se tais sintomas forem pouco frequentes.

O diagnóstico tardio decorre muitas vezes destes fatores, que resultam num mau prognóstico. Assim, espera-se que estes restrinjam o crescimento do mercado.

Aumento das questões de custo, segurança e conveniência

A leucemia é um cancro fatal, e o processo de diagnóstico da leucemia também apresenta problemas de segurança. Não é rentável. Um dos distúrbios médicos mais dispendiosos de tratar é o cancro. Os doentes oncológicos podem ser hospitalizados e receber uma variedade de terapias, como cirurgia, radioterapia e terapia sistémica. Os prémios de seguro de saúde para doentes com cancro são agora mais caros do que no passado. Além disso, os custos de copagamento, franquia e cosseguro estão a aumentar.

Doravante, o atual processo de diagnóstico da leucemia apresenta questões de segurança, custo e conveniência, que deverão funcionar como um desafio ao crescimento do mercado.

Desenvolvimento recente

Em novembro de 2022, a Canon Inc. adquiriu a Redlen Technologies Inc. (Redlen), uma das empresas líderes mundiais na criação de novas tecnologias relacionadas com o desenvolvimento e fabrico de módulos detetores semicondutores. A Canon Medical Systems Corporation (Canon Medical), uma empresa do grupo Canon Inc., desenvolveu o primeiro sistema de TC de contagem de fotões (PCCT) produzido internamente, incorporando as tecnologias avançadas da Redlen. Este sistema foi instalado no Centro Exploratório de Investigação Oncológica e Ensaios Clínicos do National Cancer Center (NCC) no Japão, onde é atualmente utilizado para conduzir investigação que explora as aplicações clínicas do PCCT.

Âmbito global do mercado de diagnóstico de leucemia mielóide aguda

O mercado global de diagnóstico da leucemia mieloide aguda está segmentado em sete segmentos notáveis com base no tipo de produto, tipo de teste, tipo de cancro, faixa etária, sexo, utilizador final e canal de distribuição. O crescimento entre estes segmentos irá ajudá-lo a analisar os principais segmentos de crescimento nas indústrias e a fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para tomar decisões estratégicas para identificar as principais aplicações do mercado.

Tipo de produto

Instrumentos
Consumíveis e acessórios

Com base no tipo de produto, o mercado está segmentado em instrumentos e consumíveis e acessórios.

Tipo de teste

Exame de sangue
Teste de imagem
Teste de Medula Óssea
Testes Genéticos
Teste de biomarcador
Imunofenotipagem
Outros

Com base no tipo de teste, o mercado está segmentado em análises ao sangue, exames de imagem, exames de medula óssea, testes genéticos, testes de biomarcadores, imunofenotipagem, entre outros.

Tipo de cancro

Mieloblástico (M0)
Mieloblástico (M1)
Mieloblástico (M2)
Promielocítico (M3)
Mielomonocítico (M4)
Monocítico (M5)
Eritroleucemia (M6)
Megacariocítico (M7)

Com base no tipo de cancro, o mercado está segmentado em mieloblástico (M0), mieloblástico (M1), mieloblástico (M2), promielocítico (M3), mielomonocítico (M4), monocítico (M5), eritroleucemia (M6) e megacariocítico (M7 ) .

Faixa etária

Abaixo de 21
21-29
30-65
65 e acima

Com base na faixa etária, o mercado está segmentado em abaixo dos 21, 21-29, 30-65 e 65 anos e acima.

Género

Macho
Fêmea

Com base no género, o mercado está segmentado em masculino e feminino.

Utilizador final

Hospital
Laboratórios Associados
Laboratórios de diagnóstico independentes
Centros de diagnóstico por imagem
Institutos de Investigação do Cancro
Outros

Com base no utilizador final, o mercado está segmentado em hospitais, laboratórios associados, laboratórios de diagnóstico independentes, centros de diagnóstico por imagem, institutos de investigação do cancro, entre outros.

Canal de Distribuição

Concurso Direto
Vendas no Retalho

Com base no canal de distribuição, o mercado está segmentado em concurso direto e vendas a retalho.

Análise/perspetivas regionais do mercado global de diagnóstico de leucemia mieloide aguda

O mercado global de diagnóstico de leucemia mieloide aguda é analisado e são fornecidos insights e tendências do tamanho do mercado por país com base no tipo de produto, tipo de teste, tipo de cancro, faixa etária, sexo, utilizador final e canal de distribuição .

Os países abrangidos neste relatório de mercado são os EUA, Canadá, México, Alemanha, Reino Unido, França, Itália, Espanha, Rússia, Países Baixos, Suíça, Bélgica, Turquia, Resto da Europa, China, Japão, Índia, Austrália, Coreia do Sul , Indonésia, Filipinas, Tailândia, Malásia, Vietname, Singapura, Resto da Ásia-Pacífico, Brasil, Argentina, Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel e Resto do Médio Oriente e África , conforme acima referido .

A América do Norte domina o mercado global de diagnóstico de leucemia mieloide aguda devido aos novos avanços tecnológicos no diagnóstico de leucemia. Os EUA dominam o mercado de diagnóstico de leucemia mieloide aguda na América do Norte devido à crescente preferência pelos exames de saúde preventivos. A Alemanha dominou o mercado europeu de diagnóstico de leucemia mieloide aguda devido aos crescentes avanços tecnológicos, utilização de instrumentos e consumíveis de diagnóstico na região, a China está a dominar o mercado de diagnóstico de leucemia mieloide aguda da Ásia-Pacífico devido aos crescentes investimentos em I&D e ao lançamento de novos produtos que estão a impulsionar o crescimento do mercado.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações nas regulamentações do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados, como vendas de novos e de reposição, demografia do país, epidemiologia de doenças e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à concorrência de marcas locais e globais e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.

Cenário competitivo e análise global da quota de mercado do diagnóstico de leucemia mielóide aguda

O panorama competitivo do mercado global de diagnóstico de leucemia mieloide aguda fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produto, largura e amplitude do produto e domínio de aplicação . Os dados acima fornecidos estão apenas relacionados com o foco das empresas em relação ao mercado.

Alguns dos principais players que operam no mercado global de diagnóstico da leucemia mieloide aguda são a CANON MEDICAL SYSTEMS CORPORATION, a Sysmex Corporation, a Epigenomics AG, a Myriad Genetics, Inc., a F. Hoffmann-La Roche Ltd, a Abbott, a QIAGEN, a Agilent Technologies, Inc. , Siemens Healthcare GmbH, BIOMERIEUX, Exact Sciences Corporation, Merck KGaA, Hologic Inc., DiaSorin SpA, Illumina, Inc., Koninklijke Philips NV, BD, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., FONAR Corp., Time Medical Holding ., Sonic Healthcare, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. Ltd, Thermo Fisher Scientific Inc. e SternMed GmbH, entre outros.

SKU-69696

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 EPIDEMIOLOGY

5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS

5.1 REGULATORY SCENARIO IN THE U.S.

5.2 REGULATORY SCENARIO IN AUSTRALIA

5.3 REGULATORY SCENARIO IN JAPAN

5.4 REGULATORY SCENARIO IN CHINA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER

6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS

6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS

6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER

6.2 RESTRAINTS

6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS

6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA

6.3 OPPORTUNITIES

6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA

6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT

6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS

6.4 CHALLENGES

6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES

6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS

7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 INSTRUMENTS

7.2.1 BIOPSY INSTRUMENTS

7.2.1.1 BONE MARROW BIOPSY

7.2.1.2 NEEDLE BIOPSY

7.2.1.3 SURGICAL BIOPSY

7.2.1.4 OTHERS

7.2.2 PATHOLOGY-BASED INSTRUMENTS

7.2.2.1 PCR INSTRUMENTS

7.2.2.2 SLIDE STAINING SYSTEMS

7.2.2.3 TISSUE PROCESSING SYSTEMS

7.2.2.4 CELL PROCESSORS

7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS

7.2.3 IMAGING INSTRUMENTS

7.2.3.1 ULTRASOUND SYSTEMS

7.2.3.2 CT SYSTEMS

7.2.3.3 MRI SYSTEMS

7.2.3.4 OTHERS

7.2.4 OTHERS

7.3 CONSUMABLES & ACCESSORIES

7.3.1 KITS

7.3.1.1 PCR KITS

7.3.1.2 DNA POLYMERASE KITS

7.3.1.3 NUCLEIC ACID ISOLATION KITS

7.3.1.4 OTHERS

7.3.2 REAGENTS

7.3.2.1 ASSAYS

7.3.2.2 BUFFERS

7.3.2.3 PRIMERS

7.3.2.4 OTHERS

7.3.3 PROBES

7.3.4 OTHER CONSUMABLES

8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE

8.1 OVERVIEW

8.2 BLOOD TEST

8.2.1 COMPLETE BLOOD COUNT (CBC)

8.2.2 BLOOD CHEMISTRY TESTS

8.2.3 OTHERS

8.3 IMAGING TEST

8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN

8.3.2 MRI

8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN

8.3.4 OTHERS

8.4 BONE MARROW TESTS

8.4.1 BONE MARROW ASPIRATE

8.4.2 BONE MARROW BIOPSY

8.4.3 OTHERS

8.5 GENETIC TESTS

8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)

8.5.2 KARYOTYPING

8.5.3 OTHERS

8.6 BIOMARKER TEST

8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER

8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER

8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER

8.7 IMMUNOPHENOTYPING

8.7.1 FLOW CYTOMETRY

8.7.2 IMMUNOHISTOCHEMISTRY

8.7.3 OTHERS

8.8 OTHERS

9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE

9.1 OVERVIEW

9.2 MYELOBLASTIC (M0)

9.3 MYELOBLASTIC (M1)

9.4 MYELOBLASTIC (M2)

9.5 PROMYELOCYTIC (M3)

9.6 MYELOMONOCYTIC (M4)

9.7 MONOCYTIC (M5)

9.8 ERYTHROLEUKEMIA (M6)

9.9 MEGAKARYOCYTIC (M7)

10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP

10.1 OVERVIEW

10.2 65 AND ABOVE

10.3 30-65

10.4 BELOW 21

10.5 21-29

11 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER

11.1 OVERVIEW

11.2 MALE

11.3 FEMALE

12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.3 ASSOCIATED LABS

12.4 INDEPENDENT DIAGNOSTIC LABORATORIES

12.5 DIAGNOSTIC IMAGING CENTERS

12.6 CANCER RESEARCH INSTITUTES

12.7 OTHERS

13 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAIL SALES

14 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION

14.1 OVERVIEW

14.2 NORTH AMERICA

14.2.1 U.S.

14.2.2 CANADA

14.2.3 MEXICO

14.3 EUROPE

14.3.1 GERMANY

14.3.2 UNITED KINGDOM

14.3.3 FRANCE

14.3.4 ITALY

14.3.5 SPAIN

14.3.6 RUSSIA

14.3.7 NETHERLANDS

14.3.8 SWITZERLAND

14.3.9 BELGIUM

14.3.10 TURKEY

14.3.11 REST OF EUROPE

14.4 ASIA-PACIFIC

14.4.1 CHINA

14.4.2 JAPAN

14.4.3 INDIA

14.4.4 AUSTRALIA

14.4.5 SOUTH KOREA

14.4.6 INDONESIA

14.4.7 PHILIPPINES

14.4.8 THAILAND

14.4.9 MALAYSIA

14.4.10 VIETNAM

14.4.11 SINGAPORE

14.4.12 REST OF ASIA-PACIFIC

14.5 SOUTH AMERICA

14.5.1 BRAZIL

14.5.2 ARGENTINA

14.5.3 REST OF SOUTH AMERICA

14.6 MIDDLE EAST AND AFRICA

14.6.1 SOUTH AFRICA

14.6.2 SAUDI ARABIA

14.6.3 U.A.E

14.6.4 EGYPT

14.6.5 ISRAEL

14.6.6 REST OF MIDDLE EAST AND AFRICA

15 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 CANON MEDICAL SYSTEMS CORPORATION.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 SYSMEX CORPORATION

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 EPIGENOMICS AG.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 MYRIAD GENETICS, INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 F. HOFFMANN- LA ROCHE LTD

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 ABBOTT

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 AGILENT TECHNOLOGIES, INC.

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 BD

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 BIOMERIEUX

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 BIO-RAD LABORATORIES, INC.

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENT

17.11 DIASORIN S.P.A.

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENTS

17.12 EXACT SCIENCES CORPORATION

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENTS

17.13 HOLOGIC INC.

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 ILLUMINA, INC.

17.14.1 COMPANY SNAPSHOT

17.14.2 REVENUE ANALYSIS

17.14.3 PRODUCT PORTFOLIO

17.14.4 RECENT DEVELOPMENT

17.15 KONINKLIJKE PHILIPS N.V.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENT

17.16 MEDONICA CO. LTD

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 MINFOUND MEDICAL SYSTEMS CO., LTD

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 PLEXBIO

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENTS

17.19 QIAGEN

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENTS

17.2 QUEST DIAGNOSTICS INCORPORATED

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENTS

17.21 SIEMENS HEALTHCARE GMBH

17.21.1 COMPANY SNAPSHOT

17.21.2 REVENUE ANALYSIS

17.21.3 PRODUCT PORTFOLIO

17.21.4 RECENT DEVELOPMENT

17.22 SONIC HEALTHCARE

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 STERNMED GMBH

17.23.1 COMPANY SNAPSHOT

17.23.2 PRODUCT PORTFOLIO

17.23.3 RECENT DEVELOPMENTS

17.24 THERMO FISHER SCIENTIFIC INC.

17.24.1 COMPANY SNAPSHOT

17.24.2 REVENUE ANALYSIS

17.24.3 PRODUCT PORTFOLIO

17.24.4 RECENT DEVELOPMENT

17.25 TIME MEDICAL HOLDING

17.25.1 COMPANY SNAPSHOT

17.25.2 PRODUCT PORTFOLIO

17.25.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Lista de Tabela

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA

TABLE 2 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 GLOBAL INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 47 GLOBAL DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 GLOBAL CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 GLOBAL OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 50 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 51 GLOBAL DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 52 GLOBAL RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 53 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 54 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 55 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 56 NORTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 57 NORTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 58 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 59 NORTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 60 NORTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 61 NORTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 73 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 74 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 75 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 76 U.S. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 77 U.S. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 78 U.S. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 79 U.S. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 80 U.S. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 81 U.S. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 82 U.S. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 83 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 84 U.S. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 85 U.S. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 86 U.S. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 87 U.S. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 88 U.S. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 89 U.S. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 90 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 91 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 92 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 93 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 94 U.S. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 95 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 96 CANADA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 97 CANADA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 98 CANADA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 99 CANADA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 100 CANADA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 101 CANADA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 102 CANADA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 103 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 104 CANADA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 105 CANADA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 106 CANADA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 107 CANADA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 108 CANADA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 109 CANADA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 110 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 111 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 112 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 113 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 114 CANADA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 116 MEXICO INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 117 MEXICO BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 118 MEXICO PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 119 MEXICO IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 120 MEXICO CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 121 MEXICO KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 122 MEXICO REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 123 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 124 MEXICO BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 125 MEXICO IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 126 MEXICO BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 127 MEXICO GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 128 MEXICO BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 129 MEXICO IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 130 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 131 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 132 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 133 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 134 MEXICO ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 135 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 136 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 137 EUROPE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 138 EUROPE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 139 EUROPE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 140 EUROPE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 141 EUROPE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 142 EUROPE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 143 EUROPE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 144 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 145 EUROPE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 146 EUROPE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 147 EUROPE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 148 EUROPE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 149 EUROPE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 150 EUROPE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 151 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 152 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 153 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 154 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 155 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 156 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 157 GERMANY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 158 GERMANY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 159 GERMANY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 160 GERMANY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 161 GERMANY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 162 GERMANY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 163 GERMANY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 164 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 165 GERMANY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 166 GERMANY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 167 GERMANY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 168 GERMANY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 169 GERMANY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 170 GERMANY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 171 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 172 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 173 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 174 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 175 GERMANY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 176 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 177 UNITED KINGDOM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 178 UNITED KINGDOM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 179 UNITED KINGDOM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 180 UNITED KINGDOM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 181 UNITED KINGDOM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 182 UNITED KINGDOM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 183 UNITED KINGDOM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 184 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 185 UNITED KINGDOM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 186 UNITED KINGDOM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 187 UNITED KINGDOM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 188 UNITED KINGDOM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 189 UNITED KINGDOM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 190 UNITED KINGDOM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 191 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 192 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 193 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 194 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 195 UNITED KINGDOM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 196 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 197 FRANCE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 198 FRANCE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 199 FRANCE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 200 FRANCE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 201 FRANCE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 202 FRANCE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 203 FRANCE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 204 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 205 FRANCE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 206 FRANCE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 207 FRANCE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 208 FRANCE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 209 FRANCE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 210 FRANCE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 211 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 212 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 213 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 214 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 215 FRANCE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 216 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 217 ITALY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 218 ITALY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 219 ITALY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 220 ITALY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 221 ITALY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 222 ITALY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 223 ITALY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 224 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 225 ITALY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 226 ITALY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 227 ITALY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 228 ITALY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 229 ITALY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 230 ITALY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 231 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 232 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 233 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 234 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 235 ITALY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 236 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 237 SPAIN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 238 SPAIN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 239 SPAIN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 240 SPAIN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 241 SPAIN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 242 SPAIN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 243 SPAIN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 244 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 245 SPAIN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 246 SPAIN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 247 SPAIN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 248 SPAIN GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 249 SPAIN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 250 SPAIN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 251 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 252 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 253 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 254 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 255 SPAIN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 256 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 257 RUSSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 258 RUSSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 259 RUSSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 260 RUSSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 261 RUSSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 262 RUSSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 263 RUSSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 264 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 265 RUSSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 266 RUSSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 267 RUSSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 268 RUSSIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 269 RUSSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 270 RUSSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 271 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 272 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 273 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 274 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 275 RUSSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 276 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 277 NETHERLANDS INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 278 NETHERLANDS BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 279 NETHERLANDS PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 280 NETHERLANDS IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 281 NETHERLANDS CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 282 NETHERLANDS KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 283 NETHERLANDS REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 284 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 285 NETHERLANDS BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 286 NETHERLANDS IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 287 NETHERLANDS BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 288 NETHERLANDS GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 289 NETHERLANDS BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 290 NETHERLANDS IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 291 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 292 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 293 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 294 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 295 NETHERLANDS ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 296 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 297 SWITZERLAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 298 SWITZERLAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 299 SWITZERLAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 300 SWITZERLAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 301 SWITZERLAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 302 SWITZERLAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 303 SWITZERLAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 304 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 305 SWITZERLAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 306 SWITZERLAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 307 SWITZERLAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 308 SWITZERLAND GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 309 SWITZERLAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 310 SWITZERLAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 311 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 312 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 313 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 314 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 315 SWITZERLAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 316 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 317 BELGIUM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 318 BELGIUM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 319 BELGIUM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 320 BELGIUM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 321 BELGIUM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 322 BELGIUM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 323 BELGIUM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 324 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 325 BELGIUM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 326 BELGIUM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 327 BELGIUM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 328 BELGIUM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 329 BELGIUM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 330 BELGIUM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 331 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 332 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 333 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 334 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 335 BELGIUM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 336 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 337 TURKEY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 338 TURKEY BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 339 TURKEY PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 340 TURKEY IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 341 TURKEY CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 342 TURKEY KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 343 TURKEY REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 344 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 345 TURKEY BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 346 TURKEY IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 347 TURKEY BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 348 TURKEY GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 349 TURKEY BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 350 TURKEY IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 351 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 352 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 353 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 354 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 355 TURKEY ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 356 REST OF EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 357 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 358 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 359 ASIA-PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 360 ASIA-PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 361 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 362 ASIA-PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 363 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 364 ASIA-PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 365 ASIA-PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 366 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 367 ASIA-PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 368 ASIA-PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 369 ASIA-PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 370 ASIA-PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 371 ASIA-PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 372 ASIA-PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 373 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 374 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 375 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 376 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 377 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 378 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 379 CHINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 380 CHINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 381 CHINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 382 CHINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 383 CHINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 384 CHINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 385 CHINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 386 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 387 CHINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 388 CHINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 389 CHINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 390 CHINA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 391 CHINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 392 CHINA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 393 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 394 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 395 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 396 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 397 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 398 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 399 JAPAN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 400 JAPAN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 401 JAPAN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 402 JAPAN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 403 JAPAN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 404 JAPAN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 405 JAPAN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 406 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 407 JAPAN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 408 JAPAN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 409 JAPAN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 410 JAPAN GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 411 JAPAN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 412 JAPAN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 413 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 414 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 415 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 416 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 417 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 418 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 419 INDIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 420 INDIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 421 INDIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 422 INDIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 423 INDIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 424 INDIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 425 INDIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 426 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 427 INDIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 428 INDIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 429 INDIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 430 INDIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 431 INDIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 432 INDIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 433 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 434 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 435 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 436 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 437 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 438 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 439 AUSTRALIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 440 AUSTRALIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 441 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 442 AUSTRALIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 443 AUSTRALIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 444 AUSTRALIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 445 AUSTRALIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 446 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 447 AUSTRALIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 448 AUSTRALIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 449 AUSTRALIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 450 AUSTRALIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 451 AUSTRALIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 452 AUSTRALIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 453 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 454 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 455 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 456 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 457 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 458 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 459 SOUTH KOREA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 460 SOUTH KOREA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 461 SOUTH KOREA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 462 SOUTH KOREA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 463 SOUTH KOREA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 464 SOUTH KOREA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 465 SOUTH KOREA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 466 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 467 SOUTH KOREA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 468 SOUTH KOREA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 469 SOUTH KOREA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 470 SOUTH KOREA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 471 SOUTH KOREA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 472 SOUTH KOREA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 473 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 474 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 475 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 476 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 477 SOUTH KOREA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 478 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 479 INDONESIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 480 INDONESIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 481 INDONESIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 482 INDONESIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 483 INDONESIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 484 INDONESIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 485 INDONESIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 486 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 487 INDONESIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 488 INDONESIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 489 INDONESIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 490 INDONESIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 491 INDONESIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 492 INDONESIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 493 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 494 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 495 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 496 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 497 INDONESIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 498 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 499 PHILIPPINES INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 500 PHILIPPINES BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 501 PHILIPPINES PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 502 PHILIPPINES IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 503 PHILIPPINES CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 504 PHILIPPINES KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 505 PHILIPPINES REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 506 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 507 PHILIPPINES BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 508 PHILIPPINES IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 509 PHILIPPINES BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 510 PHILIPPINES GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 511 PHILIPPINES BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 512 PHILIPPINES IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 513 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 514 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 515 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 516 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 517 PHILIPPINES ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 518 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 519 THAILAND INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 520 THAILAND BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 521 THAILAND PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 522 THAILAND IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 523 THAILAND CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 524 THAILAND KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 525 THAILAND REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 526 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 527 THAILAND BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 528 THAILAND IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 529 THAILAND BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 530 THAILAND GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 531 THAILAND BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 532 THAILAND IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 533 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 534 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 535 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 536 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 537 THAILAND ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 538 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 539 MALAYSIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 540 MALAYSIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 541 MALAYSIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 542 MALAYSIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 543 MALAYSIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 544 MALAYSIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 545 MALAYSIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 546 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 547 MALAYSIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 548 MALAYSIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 549 MALAYSIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 550 MALAYSIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 551 MALAYSIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 552 MALAYSIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 553 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 554 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 555 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 556 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 557 MALAYSIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 558 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 559 VIETNAM INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 560 VIETNAM BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 561 VIETNAM PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 562 VIETNAM IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 563 VIETNAM CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 564 VIETNAM KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 565 VIETNAM REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 566 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 567 VIETNAM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 568 VIETNAM IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 569 VIETNAM BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 570 VIETNAM BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 571 VIETNAM GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 572 VIETNAM BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 573 VIETNAM IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 574 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 575 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 576 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 577 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 578 VIETNAM ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 579 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 580 SINGAPORE INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 581 SINGAPORE BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 582 SINGAPORE PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 583 SINGAPORE IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 584 SINGAPORE CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 585 SINGAPORE KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 586 SINGAPORE REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 587 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 588 SINGAPORE BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 589 SINGAPORE IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 590 SINGAPORE BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 591 SINGAPORE GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 592 SINGAPORE BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 593 SINGAPORE IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 594 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 595 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 596 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 597 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 598 SINGAPORE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 599 REST OF ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 600 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 601 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 602 SOUTH AMERICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 603 SOUTH AMERICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 604 SOUTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 605 SOUTH AMERICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 606 SOUTH AMERICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 607 SOUTH AMERICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 608 SOUTH AMERICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 609 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 610 SOUTH AMERICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 611 SOUTH AMERICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 612 SOUTH AMERICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 613 SOUTH AMERICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 614 SOUTH AMERICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 615 SOUTH AMERICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 616 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 617 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 618 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 619 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 620 SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 621 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 622 BRAZIL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 623 BRAZIL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 624 BRAZIL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 625 BRAZIL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 626 BRAZIL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 627 BRAZIL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 628 BRAZIL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 629 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 630 BRAZIL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 631 BRAZIL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 632 BRAZIL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 633 BRAZIL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 634 BRAZIL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 635 BRAZIL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 636 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 637 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 638 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 639 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 640 BRAZIL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 641 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 642 ARGENTINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 643 ARGENTINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 644 ARGENTINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 645 ARGENTINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 646 ARGENTINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 647 ARGENTINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 648 ARGENTINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 649 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 650 ARGENTINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 651 ARGENTINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 652 ARGENTINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 653 ARGENTINA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 654 ARGENTINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 655 ARGENTINA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 656 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 657 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 658 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 659 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 660 ARGENTINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 661 REST OF SOUTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 662 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 663 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 664 MIDDLE EAST AND AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 665 MIDDLE EAST AND AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 666 MIDDLE EAST AND AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 667 MIDDLE EAST AND AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 668 MIDDLE EAST AND AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 669 MIDDLE EAST AND AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 670 MIDDLE EAST AND AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 671 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 672 MIDDLE EAST AND AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 673 MIDDLE EAST AND AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 674 MIDDLE EAST AND AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 675 MIDDLE EAST AND AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 676 MIDDLE EAST AND AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 677 MIDDLE EAST AND AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 678 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 679 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 680 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 681 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 682 MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 683 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 684 SOUTH AFRICA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 685 SOUTH AFRICA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 686 SOUTH AFRICA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 687 SOUTH AFRICA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 688 SOUTH AFRICA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 689 SOUTH AFRICA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 690 SOUTH AFRICA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 691 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 692 SOUTH AFRICA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 693 SOUTH AFRICA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 694 SOUTH AFRICA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 695 SOUTH AFRICA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 696 SOUTH AFRICA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 697 SOUTH AFRICA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 698 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 699 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 700 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 701 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 702 SOUTH AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 703 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 704 SAUDI ARABIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 705 SAUDI ARABIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 706 SAUDI ARABIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 707 SAUDI ARABIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 708 SAUDI ARABIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 709 SAUDI ARABIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 710 SAUDI ARABIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 711 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 712 SAUDI ARABIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 713 SAUDI ARABIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 714 SAUDI ARABIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 715 SAUDI ARABIA GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 716 SAUDI ARABIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 717 SAUDI ARABIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 718 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 719 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 720 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 721 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 722 SAUDI ARABIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 723 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 724 U.A.E. INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 725 U.A.E. BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 726 U.A.E. PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 727 U.A.E. IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 728 U.A.E. CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 729 U.A.E. KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 730 U.A.E. REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 731 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 732 U.A.E. BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 733 U.A.E. IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 734 U.A.E. BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 735 U.A.E. GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 736 U.A.E. BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 737 U.A.E. IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 738 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 739 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 740 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 741 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 742 U.A.E. ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 743 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 744 EGYPT INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 745 EGYPT BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 746 EGYPT PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 747 EGYPT IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 748 EGYPT CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 749 EGYPT KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 750 EGYPT REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 751 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 752 EGYPT BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 753 EGYPT IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 754 EGYPT BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 755 EGYPT GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 756 EGYPT BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 757 EGYPT IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 758 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 759 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 760 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 761 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 762 EGYPT ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 763 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 764 ISRAEL INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 765 ISRAEL BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 766 ISRAEL PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 767 ISRAEL IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 768 ISRAEL CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 769 ISRAEL KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 770 ISRAEL REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 771 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 772 ISRAEL BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 773 ISRAEL IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 774 ISRAEL BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 775 ISRAEL GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 776 ISRAEL BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 777 ISRAEL IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2022-2031 (USD MILLION)

TABLE 778 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2022-2031 (USD MILLION)

TABLE 779 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 780 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 781 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 782 ISRAEL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 783 REST OF MIDDLE EAST AND AFRICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

Lista de Figura

FIGURE 1 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD

FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2024 & 2031

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD

FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET MANUFACTURERS IN THE FORECAST PERIOD

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET

FIGURE 16 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)

FIGURE 17 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES)

FIGURE 18 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023

FIGURE 19 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)

FIGURE 20 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)

FIGURE 21 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 22 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023

FIGURE 23 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2024-2031 (USD MILLION)

FIGURE 24 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2024-2031)

FIGURE 25 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 26 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023

FIGURE 27 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2024-2031 (USD MILLION)

FIGURE 28 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2024-2031)

FIGURE 29 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE

FIGURE 30 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023

FIGURE 31 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)

FIGURE 32 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2024-2031)

FIGURE 33 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 34 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023

FIGURE 35 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 36 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 37 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 38 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023

FIGURE 39 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 40 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2024-2031)

FIGURE 41 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 43 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 44 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 45 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2023)

FIGURE 47 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2023(%)

FIGURE 48 NORTH AMERICA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

FIGURE 49 EUROPE ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

FIGURE 50 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

How big is the Acute Myeloid Leukemia Diagnostics Market?

The Acute Myeloid Leukemia Diagnostics Market size will be worth USD 6,538.78 million by 2031.

What is the growth rate of the Acute Myeloid Leukemia Diagnostics Market?

The Acute Myeloid Leukemia Diagnostics Market growth rate is 11.3% during the forecast period.

What are the growth drivers of the Acute Myeloid Leukemia Diagnostics Market?

Increase in Awareness Regarding Leukemia Cancer, Novel Technological Advancements in Leukemia Diagnostics and the Growing Prevalence of Leukemia Cancer are the growth drivers of the Acute Myeloid Leukemia Diagnostics Market.

What are the factors on which the Acute Myeloid Leukemia Diagnostics Market research is based on?

The product type, test type, cancer type, age group, gender, end user, and distribution channel are the factors on which the Acute Myeloid Leukemia Diagnostics Market research is based.

Which are the major companies in the Acute Myeloid Leukemia Diagnostics Market?

Major companies in the Acute Myeloid Leukemia Diagnostics Market are CANON MEDICAL SYSTEMS CORPORATION, Sysmex Corporation, Epigenomics AG, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, Agilent Technologies, Inc., Siemens Healthcare GmbH, BIOMERIEUX, Exact Sciences Corporation, Merck KGaA, Hologic Inc., DiaSorin S.p.A., Illumina, Inc., Koninklijke Philips N.V., BD, Quest Diagnostics Incorporated, Bio-Rad Laboratories, Inc., FONAR Corp., Time Medical Holding., Sonic Healthcare, PlexBio, MinFound Medical Systems Co., Ltd, Medonica Co. Ltd, Thermo Fisher Scientific Inc., and SternMed GmbH.

Mercado Global de Diagnóstico de Leucemia Mieloide Aguda – Tendências do setor e previsão para 2031

Mercado Global de Diagnóstico de Leucemia Mieloide Aguda – Tendências do setor e previsão para 2031

Global Acute Myeloid Leukemia Diagnostics Market

CAGR : 11.30 %

Análise e insights de mercado de diagnóstico de leucemia mieloide aguda

Dinâmica global do mercado de diagnóstico da leucemia mieloide aguda

Âmbito global do mercado de diagnóstico de leucemia mielóide aguda

Análise/perspetivas regionais do mercado global de diagnóstico de leucemia mieloide aguda

Cenário competitivo e análise global da quota de mercado do diagnóstico de leucemia mielóide aguda

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Relatórios

Informações de mercado

Apoiar

Soluções

Mercado Global de Diagnóstico de Leucemia Mieloide Aguda – Tendências do setor e previsão para 2031

Mercado Global de Diagnóstico de Leucemia Mieloide Aguda – Tendências do setor e previsão para 2031

Global Acute Myeloid Leukemia Diagnostics Market

CAGR : 11.30 %

Análise e insights de mercado de diagnóstico de leucemia mieloide aguda

Dinâmica global do mercado de diagnóstico da leucemia mieloide aguda

Âmbito global do mercado de diagnóstico de leucemia mielóide aguda

Análise/perspetivas regionais do mercado global de diagnóstico de leucemia mieloide aguda

Cenário competitivo e análise global da quota de mercado do diagnóstico de leucemia mielóide aguda

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas